Please find enclosed a copy of Unaudited Financial Results for the quarter ended 31st March 2026
RESULTS
◆ Monitor Closely
MEDIUM RISK
📅 Filed on BSE: 28 Apr 2026, 06:46 PM IST · BSE ID: c5c9521d-8973-4167-9f0b-46f9c26fa956
View Original BSE Filing (PDF)
💡
In Simple Terms
Sanofi India reported quarterly results with insulin drug sales growing 19% year-over-year, but overall revenue down due to partnership changes. The board appointed a new chairman and replaced two retiring directors.
🤖 AI Summary
- Q4 FY26 revenue ₹4,723 Million; insulin portfolio achieved 19% YoY growth and 14% sequential growth
- Overall quarter impacted by partnership transition transactions affecting reported revenue
- Rahul Bhatnagar appointed chairman effective 30 April 2026; two independent directors departed
- All five board committees reconstituted with new composition; new audit and risk management structures
- Export sales stabilizing despite geopolitical situation; company driving operational efficiency improvements
🔢 Key Numbers — exact figures from BSE filing, not rounded
Q4 FY26 Revenue from Operations
₹4,723 Million
-12.1%
Q4 FY25 Revenue from Operations
₹5,359 Million
FY26 Full-Year Total Income
₹18,571 Million
Q4 FY26 Total Income
₹4,767 Million
-11.6%
Insulin Portfolio YoY Growth
19%
Insulin Portfolio Sequential Growth
14%
🏢 How This Affects the Company
Insulin portfolio segment demonstrating sustained strength with 19% YoY and 14% sequential growth, validating market position in diabetes injectables. Overall quarter revenue decline reflects partnership transition activities rather than core business deterioration.
Q4 FY26 total income ₹4,767 Million versus ₹5,392 Million in Q4 FY25 (down 11.6%). FY26 full-year total income ₹18,571 Million. Operating margins and profitability metrics require full financial statement review pending standard disclosure.
Board leadership transition from two independent directors to new chairman Rahul Bhatnagar effective 30 April 2026. Committee reconstitution maintains governance structure with focus on audit, risk management, and stakeholder relations oversight.
Partnership transitions created near-term revenue headwinds; geopolitical pressures affecting export segment. Leadership transition during active business cycle requires continuity monitoring. No material adverse risks disclosed.
👥 What This Means For Shareholders
✅
Action Required
No action required. Review Q1 FY27 results when announced to confirm post-transition operational stability and partnership impact duration.
👤
Who Is Affected
All equity shareholders. Leadership transition affects board-level governance; partnership realignment impacts revenue recognition timing but not long-term shareholder value creation. No dividend or capital restructuring announced.
🔍
Management Signal
Appointment of established independent director Rahul Bhatnagar as chairman signals governance continuity. Emphasis on insulin portfolio growth and strategic partnerships reflects confidence in injectable diabetes segment viability despite sector trends favoring newer therapies.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q1 FY27 results announcement — verify if partnership transition impacts normalize and insulin growth sustains
Board committee meeting minutes — track new chairman's strategic priorities and partnership implementation timeline
Next independent director appointments — monitor timing and profile given two director departures effective 29 April 2026
MEDIUM RISK
Partnership transitions created near-term revenue impact; leadership transition during active business cycle requires continuity assurance. Export headwinds persist. Monitor Q1 FY27 stabilization.
💡 Investor Takeaway
Sanofi India Q4 FY26 revenue ₹4,723 Million reflects 11.6% YoY decline driven by partnership transitions, but insulin portfolio achieved 19% YoY growth validating core franchise strength. Leadership transition to new chairman now effective; full-year FY26 total income ₹18,571 Million.
⚖️ Strengths & Concerns
✅ Positives
- Insulin portfolio achieved 19% YoY growth and 14% sequential growth, validating clinical demand and market position
- Export sales stabilizing despite geopolitical challenges; company executing targeted efficiency improvements and market initiatives
⚠️ Concerns
- Q4 FY26 revenue ₹4,723 Million down from ₹5,359 Million in Q4 FY25, with partnership transitions cited as primary headwind
- Overall quarterly results impacted by transaction-related activities; core segment performance masked by partnership realignment costs
📅 Company Track Record
Sanofi India incorporated 1956. Prior filing 20 April 2026 announced board meeting scheduled for 28 April 2026 to approve Q4 FY26 results. This filing confirms approval and reports completed board transitions.
Based on publicly available historical data. For context only.